ATXS
Price
$7.52
Change
+$0.52 (+7.43%)
Updated
Sep 5 closing price
Capitalization
424.39M
67 days until earnings call
KALV
Price
$15.82
Change
+$0.62 (+4.08%)
Updated
Sep 5 closing price
Capitalization
796.38M
5 days until earnings call
Interact to see
Advertisement

ATXS vs KALV

Header iconATXS vs KALV Comparison
Open Charts ATXS vs KALVBanner chart's image
Astria Therapeutics
Price$7.52
Change+$0.52 (+7.43%)
Volume$543.12K
Capitalization424.39M
KalVista Pharmaceuticals
Price$15.82
Change+$0.62 (+4.08%)
Volume$1.08M
Capitalization796.38M
ATXS vs KALV Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. KALV commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a StrongBuy and KALV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ATXS: $7.52 vs. KALV: $15.82)
Brand notoriety: ATXS and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 205% vs. KALV: 86%
Market capitalization -- ATXS: $424.39M vs. KALV: $796.38M
ATXS [@Biotechnology] is valued at $424.39M. KALV’s [@Biotechnology] market capitalization is $796.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, KALV is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while KALV’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 3 bearish.
  • KALV’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than KALV.

Price Growth

ATXS (@Biotechnology) experienced а +21.68% price change this week, while KALV (@Biotechnology) price change was +17.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 12, 2025.

KALV is expected to report earnings on Sep 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KALV($796M) has a higher market cap than ATXS($424M). KALV YTD gains are higher at: 86.777 vs. ATXS (-15.884). ATXS has higher annual earnings (EBITDA): -131.42M vs. KALV (-173.33M). ATXS has more cash in the bank: 259M vs. KALV (221M). ATXS has less debt than KALV: ATXS (4.77M) vs KALV (6.31M). ATXS (0) and KALV (0) have equivalent revenues.
ATXSKALVATXS / KALV
Capitalization424M796M53%
EBITDA-131.42M-173.33M76%
Gain YTD-15.88486.777-18%
P/E RatioN/AN/A-
Revenue00-
Total Cash259M221M117%
Total Debt4.77M6.31M76%
FUNDAMENTALS RATINGS
ATXS vs KALV: Fundamental Ratings
ATXS
KALV
OUTLOOK RATING
1..100
1912
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
5644
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (56) in the Biotechnology industry is in the same range as KALV (60) in the Pharmaceuticals Other industry. This means that ATXS’s stock grew similarly to KALV’s over the last 12 months.

KALV's Profit vs Risk Rating (89) in the Pharmaceuticals Other industry is in the same range as ATXS (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (98) in the Biotechnology industry is in the same range as KALV (99) in the Pharmaceuticals Other industry. This means that ATXS’s stock grew similarly to KALV’s over the last 12 months.

KALV's Price Growth Rating (44) in the Pharmaceuticals Other industry is in the same range as ATXS (56) in the Biotechnology industry. This means that KALV’s stock grew similarly to ATXS’s over the last 12 months.

KALV's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ATXS (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSKALV
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DQIRX34.56N/A
N/A
BNY Mellon Equity Income Fund I
SRIDX14.68N/A
N/A
Gabelli SRI I
MKVEX16.60N/A
N/A
MFS International Large Cap Value R2
GSTIX15.16-0.02
-0.13%
Goldman Sachs Strategic Growth Instl
BPSIX28.31-0.05
-0.18%
Boston Partners Small Cap Value II I

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with CRNX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+7.43%
CRNX - ATXS
54%
Loosely correlated
+3.97%
XENE - ATXS
50%
Loosely correlated
+1.48%
NRIX - ATXS
50%
Loosely correlated
+8.66%
DNLI - ATXS
50%
Loosely correlated
+4.33%
OCUL - ATXS
50%
Loosely correlated
+7.09%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
+4.08%
ATXS - KALV
46%
Loosely correlated
+7.43%
COGT - KALV
43%
Loosely correlated
+0.85%
IRON - KALV
41%
Loosely correlated
+0.95%
IDYA - KALV
40%
Loosely correlated
+5.15%
SYRE - KALV
39%
Loosely correlated
+0.06%
More